11 – 20 of 20
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2017
-
Mark
Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.
(
- Contribution to journal › Article
-
Mark
Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors
(
- Contribution to journal › Article
- 2016
-
Mark
Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels.
(
- Contribution to journal › Scientific review
-
Mark
Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors
(
- Contribution to journal › Article
- 2015
-
Mark
Switching treatments in haemophilia: is there a risk of inhibitor development?
(
- Contribution to journal › Scientific review
-
Mark
Rationale for individualizing haemophilia care.
(
- Contribution to journal › Scientific review
- 2014
-
Mark
Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?
(
- Contribution to journal › Scientific review
- 2013
-
Mark
Factor VIII Products and Inhibitor Development in Severe Hemophilia A
(
- Contribution to journal › Article
-
Mark
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A
(
- Contribution to journal › Article
- 2012
-
Mark
Beyond patient benefit: clinical development in hemophilia
(
- Contribution to journal › Scientific review
- « previous
- 1
- 2
- next »